Add like
Add dislike
Add to saved papers

Up-regulation of C5orf34 promotes lung adenocarcinoma migration and is correlated with worse prognosis.

Gene 2019 Februrary 14
OBJECTIVE: This study aimed to investigate the biological role of C5orf34 in Lung adenocarcinoma (LAD) and the mechanism of such role.

METHODS: The mRNA expression of C5orf34 was analyzed using student's t-test based on the data obtained from TCGA database. Kaplan-Meier analysis was performed to evaluate the prognosis value of C5orf34. Chi-square (χ2 ) test was performed to analyze the correlation between C5orf34 expression and clinical features. The effect of C5orf34 siRNA on A549 and SPCA1 cells proliferation and migration were explored using CCK8 assay, wound healing assay and transwell assays, respectively. Western blot was performed to evaluate the expression of C5orf34, ERK, p-ERK, MEK and p-MEK.

RESULTS: C5orf34 expression was enhanced in LAD and positively correlated with poor prognosis in patients with LAD. χ2 test revealed that C5orf34 expression was obviously associated with age (p = 0.016), Pathologic-Stage (p = 0.045) and Pathologic-N (p = 0.023). In addition, knockdown of C5orf34 significantly suppressed A549 and SPCA1 cells proliferation and motility (p < 0.01) in vitro. Moreover, by western blot analysis, we found that depleting C5orf34 remarkably reduced the ratio of p-MEK/MEK and p-ERK/ERK in A549 cells.

CONCLUSION: Our results firstly revealed that C5orf34 might play a facilitating role in LAD development and progression by regulating MAPK signaling pathway. Furthermore, our data implied that C5orf34 may be a potential predictor and treatment target for LAD.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app